The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final analysis of the NEOMET trial of neoadjuvant metformin: Examining effects on Ki67, gene expression, and pathway analysis in primary operable breast cancer.
A. M. Thompson
No relevant relationships to disclose
T. Iwamoto
No relevant relationships to disclose
L. Jordan
No relevant relationships to disclose
C. Purdie
No relevant relationships to disclose
S. E. Bray
No relevant relationships to disclose
L. Baker
No relevant relationships to disclose
G. Hardie
No relevant relationships to disclose
L. Pusztai
No relevant relationships to disclose
S. L. Moulder
No relevant relationships to disclose
J. A. Dewar
No relevant relationships to disclose
S. M. Hadad
No relevant relationships to disclose